NO20043401L - Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IGFBP-5 og fremgangsmater for a anvende slike - Google Patents

Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IGFBP-5 og fremgangsmater for a anvende slike

Info

Publication number
NO20043401L
NO20043401L NO20043401A NO20043401A NO20043401L NO 20043401 L NO20043401 L NO 20043401L NO 20043401 A NO20043401 A NO 20043401A NO 20043401 A NO20043401 A NO 20043401A NO 20043401 L NO20043401 L NO 20043401L
Authority
NO
Norway
Prior art keywords
igfbp
antisense oligonucleotides
bise
methods
inhibit
Prior art date
Application number
NO20043401A
Other languages
English (en)
Other versions
NO333017B1 (no
Inventor
Martin Gleave
Maxim Signaevsky
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of NO20043401L publication Critical patent/NO20043401L/no
Publication of NO333017B1 publication Critical patent/NO333017B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bispesifikke antisense-oligonukleotider som hovedsakelig består av en sekvens av baser som er komplementær med deler av både genet som koder for humant IGFBP-2 og genet som koder for humant IGFBP-5 og som er nyttige som antisense-terapeutiske midler ved behandling av endokrin-regulerte cancere
NO20043401A 2002-01-17 2004-08-16 Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IFGBP-5 og anvendelse av slike samt farmasoytisk sammensetning og fremgangsmate for a fremstille denne. NO333017B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35004602P 2002-01-17 2002-01-17
PCT/CA2003/000061 WO2003062421A1 (en) 2002-01-17 2003-01-17 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same

Publications (2)

Publication Number Publication Date
NO20043401L true NO20043401L (no) 2004-10-13
NO333017B1 NO333017B1 (no) 2013-02-18

Family

ID=27613360

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043401A NO333017B1 (no) 2002-01-17 2004-08-16 Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IFGBP-5 og anvendelse av slike samt farmasoytisk sammensetning og fremgangsmate for a fremstille denne.

Country Status (15)

Country Link
US (11) US20030158143A1 (no)
EP (1) EP1465995B1 (no)
JP (1) JP4491240B2 (no)
KR (2) KR101166214B1 (no)
AT (1) ATE402999T1 (no)
AU (1) AU2003237616B2 (no)
CA (1) CA2469685C (no)
DE (1) DE60322509D1 (no)
DK (1) DK1465995T3 (no)
ES (1) ES2307942T3 (no)
HU (1) HU229452B1 (no)
IL (2) IL162540A0 (no)
NO (1) NO333017B1 (no)
NZ (1) NZ533126A (no)
WO (1) WO2003062421A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100768109B1 (ko) 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
NZ533126A (en) * 2002-01-17 2006-04-28 Univ British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
CA2494766C (en) 2002-08-21 2015-05-12 The University Of British Columbia Rnai probes targeting cancer-related proteins
ATE478142T1 (de) * 2002-08-21 2010-09-15 Univ British Columbia Behandlung von melanomen durch reduktion der clusterin menge
EP1560933A4 (en) * 2002-11-14 2007-11-21 Wyeth Corp METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS
EP1667731B1 (en) * 2003-10-01 2013-05-22 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
DK1814595T3 (da) * 2004-11-23 2014-03-31 Univ British Columbia Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne
US7315916B2 (en) * 2004-12-16 2008-01-01 Sandisk Corporation Scratch pad block
WO2007030930A1 (en) * 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
HRP20191129T1 (hr) 2009-11-24 2019-09-20 Alethia Biotherapeutics Inc. Anti-klusterinska protutijela i ulomci koji vežu antigen i njihova uporaba za smanjivanje volumena tumora
SG183114A1 (en) 2010-03-01 2012-09-27 Tau Therapeutics Llc Cancer diagnosis and imaging
WO2012156817A2 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer
SG10201601917XA (en) 2011-09-12 2016-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
EA201491568A1 (ru) 2012-02-22 2014-11-28 Алетиа Байотерапьютикс Инк. Совместное применение ингибитора кластерина и ингибитора egfr для лечения рака
CA2844640A1 (en) * 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
US9744187B2 (en) * 2015-10-14 2017-08-29 Bio-Path Holdings, Inc. p-Ethoxy nucleic acids for liposomal formulation
EP3364993B1 (en) 2015-10-22 2022-11-09 Cavion, Inc. Methods for treating angelman syndrome
US10496215B2 (en) * 2016-04-29 2019-12-03 Synaptics Incorporated Sensing for touch and force
EP3512525B1 (en) 2016-09-16 2022-07-27 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
EP3585376A4 (en) 2017-02-15 2020-11-25 Cavion, Inc. CALCIUM CHANNELS INHIBITORS
EA201992490A1 (ru) 2017-04-19 2020-03-03 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования bcl2
US11041153B2 (en) 2017-04-19 2021-06-22 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for STAT3 inhibition
KR102654466B1 (ko) 2017-04-26 2024-04-08 카비온, 인코포레이티드 기억 및 인지 개선 방법 및 기억 및 인지 장애 치료 방법
KR102068302B1 (ko) 2018-07-25 2020-01-20 정준모 봉투 고정장치
EP3860571A4 (en) 2018-10-03 2022-06-29 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0546110B1 (en) 1990-08-28 2001-11-14 Chiron Corporation New insulin-like growth factor binding protein igfbp-5
EP0546074B1 (en) 1990-08-28 2001-11-14 Chiron Corporation Genetic material encoding igfbp-5
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
DE69432315T2 (de) * 1993-12-23 2004-02-12 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
CA2246229C (en) * 1996-02-14 2011-08-23 Isis Pharmaceuticals Inc. Sugar-modified gapped oligonucleotides
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
JP3687900B2 (ja) 1998-11-19 2005-08-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー チロシンキナーゼの不可逆的阻害剤であるｎ−［４−（３−クロロ−４−フルオロフェニルアミノ）−７−（３−モルホリン−４−イルプロポキシ）キナゾリン−６−イル］アクリルアミド
US6464975B2 (en) 1998-12-11 2002-10-15 The Research Foundation Of State University Of New York Compositions and methods for altering cell migration
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
KR100768109B1 (ko) 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2000069454A1 (en) * 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
WO2000078341A1 (en) * 1999-06-21 2000-12-28 Murdoch Childrens Research Institute A method for the prophylaxis and/or treatment of medical disorders
AU779612C (en) 1999-07-02 2005-12-15 Genentech Inc. Peptide compounds that bind HER2
ATE393220T1 (de) * 1999-07-19 2008-05-15 Univ British Columbia Antisense-therapie für hormonregulierte tumoren
US6310047B1 (en) * 1999-08-24 2001-10-30 Virginia Commonwealth University High affinity DNA binding compounds as adjuvants in antisense technology
WO2001046455A2 (en) 1999-12-21 2001-06-28 Yale University Survivin promotion of angiogenesis
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
NZ553687A (en) * 2000-03-30 2010-03-26 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
EP1317470B1 (en) * 2000-09-14 2011-04-27 The University Of British Columbia Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate tumor therapy
DE60130583T3 (de) * 2000-12-01 2018-03-22 Europäisches Laboratorium für Molekularbiologie Kleine rns moleküle, die rns-interferenz vermitteln
EP1390472A4 (en) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
DE10152005A1 (de) 2001-10-22 2003-04-30 Bayer Cropscience Ag Pyrazolylsubstituierte Heterocyclen
US20050123896A1 (en) 2001-10-25 2005-06-09 Benz Christopher C. Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
NZ533126A (en) * 2002-01-17 2006-04-28 Univ British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
WO2003097855A2 (en) * 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
CA2494766C (en) 2002-08-21 2015-05-12 The University Of British Columbia Rnai probes targeting cancer-related proteins
ATE478142T1 (de) 2002-08-21 2010-09-15 Univ British Columbia Behandlung von melanomen durch reduktion der clusterin menge
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
EP1667731B1 (en) * 2003-10-01 2013-05-22 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
BR112012002102A2 (pt) * 2009-07-30 2017-05-02 Antisense Pharma Gmbh composição farmaceutica e metodo para preparar uma composição farmaceutica

Also Published As

Publication number Publication date
US20120220646A1 (en) 2012-08-30
US20130303592A1 (en) 2013-11-14
HU229452B1 (en) 2013-12-30
KR20110026023A (ko) 2011-03-14
US8389491B2 (en) 2013-03-05
CA2469685A1 (en) 2003-07-31
US8580761B2 (en) 2013-11-12
HUP0402543A2 (hu) 2005-03-29
US8470796B2 (en) 2013-06-25
US20160002630A1 (en) 2016-01-07
US9101646B2 (en) 2015-08-11
AU2003237616B2 (en) 2007-07-05
NZ533126A (en) 2006-04-28
IL162540A (en) 2011-06-30
US8835401B2 (en) 2014-09-16
IL162540A0 (en) 2005-11-20
HUP0402543A3 (en) 2012-09-28
US20060122141A1 (en) 2006-06-08
KR101265180B1 (ko) 2013-05-29
NO333017B1 (no) 2013-02-18
US20110196019A1 (en) 2011-08-11
US8252765B2 (en) 2012-08-28
US20080261912A1 (en) 2008-10-23
ES2307942T3 (es) 2008-12-01
US8541390B2 (en) 2013-09-24
JP4491240B2 (ja) 2010-06-30
DE60322509D1 (de) 2008-09-11
CA2469685C (en) 2013-03-12
DK1465995T3 (da) 2008-10-20
EP1465995B1 (en) 2008-07-30
KR20040085150A (ko) 2004-10-07
EP1465995A1 (en) 2004-10-13
US20100267808A1 (en) 2010-10-21
KR101166214B1 (ko) 2012-07-16
ATE402999T1 (de) 2008-08-15
US7973017B2 (en) 2011-07-05
US20030158143A1 (en) 2003-08-21
US7928082B2 (en) 2011-04-19
US20130096180A1 (en) 2013-04-18
US20110190382A1 (en) 2011-08-04
WO2003062421A1 (en) 2003-07-31
JP2005514948A (ja) 2005-05-26
US20120077861A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
NO20043401L (no) Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IGFBP-5 og fremgangsmater for a anvende slike
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
EP1628623A4 (en) METHOD FOR THE TREATMENT OF DISEASES WITH HSP90-INHIBITING AGENTS COMBINED WITH ENZYME-INHIBITORS
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
MY151032A (en) Treatment of tnf? related disorders
AU2003213771A8 (en) Method for modification of radiotherapy treatment delivery
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
IL172418A0 (en) Therapeutic agents useful for treating pain
IL164808A0 (en) Treatment of hypertesion in women receiving hormone replacement therapy
IL175427A0 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
AU2003287254A8 (en) Inhibition of gene expression using rna interfering agents
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
TW200508233A (en) Chk-1 inhibitors
AU2003243059A8 (en) Use of repression blocking sequences in methods for enhancing gene expression
EP1579010A4 (en) SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION AND METHODS OF TREATMENT
MXPA05008817A (es) Derivados de esteres lipidos de nucleotidos.
PL377040A1 (pl) Sposób leczenia zawału mięśnia sercowego
PT1163333E (pt) ''inibidores da síntese de endotelina-1''
IL176239A0 (en) Use of gaboxadol for treating insomnia
IL154293A0 (en) Process of treating dates
MX2007004259A (es) Uso de compuestos organicos.
AR034022A1 (es) Acridinas como estimuladoras de la apoptosis mediada por fas
TW200509891A (en) Selective serotonin reuptake inhibitors in the treatment of disease
IL165935A0 (en) Use of vasopeptidase inhibitors in the treatment of nephropathy

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees